Virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy for 96 weeks: a retrospective multicenter european study (SAVE-D)
M.P. Anolli,E. Degasperi,M. Jachs,T. Reiberger,V. De Ledinghen,S. Metivier,G. D'Offizi,F. di Maria,C. Schramm,H. Schmidt,C. Zöllner,F. Tacke,C. Dietz-Fricke,H. Wedemeyer,M. Papatheodoridi,G. Papatheodoridis,F. Van Bömmel,M.R. Brunetto,G. Verucchi,A. Ciancio,F. Zoulim,A. Mangia,M.N. Hilleret,U. Merle,T.A. Santantonio,N. Coppola,A. Pellicelli,B. Roche,X. Causse,L. D'Alteroche,J. Dumortier,N. Ganne,F. Heluwaert,I. Ollivier,A. Loglio,M. Viganò,A. Federico,F. Pileri,M. Maracci,M. Tonnini,J.P. Arpurt,K.l. Barange,E. Billaud,S. Pol,A. Gervais,A. Minello,I. Rosa,M. Puoti,P. Lampertico
DOI: https://doi.org/10.1016/j.dld.2024.01.011
IF: 5.165
2024-02-01
Digestive and Liver Disease
Abstract:Background Bulevirtide (BLV) received EMA approval for treatment of chronic compensated hepatitis due to Delta virus (HDV) infection, however real-life data in large cohorts of patients with cirrhosis are lacking. Methods Consecutive HDV patients with cirrhosis starting BLV 2 mg/day since September 2019 were included in a retrospective multicenter real-life European study (SAVE-D). Patients’ characteristics before and during BLV treatment were collected. Virological, biochemical, combined responses, adverse events and liver-related events (HCC, decompensation, liver transplant) were assessed. Results 215 patients with HDV compensated (CPT-A) cirrhosis receiving BLV monotherapy for a median of 72 (24-120) weeks were included: at BLV start, age was 49 (18-81) years, 60% men, ALT 78 (23-1,074) U/L, liver stiffness measurement (LSM) 18.3 (6.4-75.0) kPa, platelets 91 (17-454) x 103/mm3, 54% with varices, 8% HIV-positive, 6% with previous ascites, 6% with active HCC, 91% on NUC, median HDV RNA 5.5 (1.5-8.5) log IU/mL and HBsAg 3.7 (0.8-4.7) log IU/mL. Virological responses and HDV-RNA undetectability at W24, W48, W72, W96 were 54%, 68%, 68%, 77% and 18%, 32%, 41% and 46%, respectively. Biochemical and combined responses were 54%, 63%, 60%, 57%, and 34%, 48%, 48%, and 50%, respectively. Patients with <1 log HDV-RNA decline vs. baseline declined from 21% at W24 to 8% at W96. AST, GGT, albumin, IgG and LSM values significantly improved throughout treatment. Bile acids significantly increased, 9% patients reported mild and transient pruritus, 3% injection site reactions. The W96 cumulative risks of de-novo HCC (n=7) and decompensation (n=6) were 3.8% (95% CI 2-7%) and 3.2% (95% CI 1-6%), respectively. 7 patients underwent liver transplantation and 4 died of BLV-unrelated causes. Conclusions BLV 2 mg/day monotherapy up to 96 weeks was safe and effective in patients with HDV-related compensated cirrhosis. Virological and clinical responses increased over time and liver-related events were few.
gastroenterology & hepatology